Cargando…
Roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: A case report
BACKGROUND: Most cancer patients are accompanied by anemia, which will be more serious when combined with end-stage renal disease (ESRD). At present, cancer-related anemia and renal anemia treatments mainly include erythropoiesis-stimulating agents (ESAs), iron supplementation, and blood transfusion...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294907/ https://www.ncbi.nlm.nih.gov/pubmed/35979316 http://dx.doi.org/10.12998/wjcc.v10.i19.6587 |
_version_ | 1784749948708847616 |
---|---|
author | Zhou, Qiao-Qiao Li, Jing Liu, Bin Wang, Chun-Li |
author_facet | Zhou, Qiao-Qiao Li, Jing Liu, Bin Wang, Chun-Li |
author_sort | Zhou, Qiao-Qiao |
collection | PubMed |
description | BACKGROUND: Most cancer patients are accompanied by anemia, which will be more serious when combined with end-stage renal disease (ESRD). At present, cancer-related anemia and renal anemia treatments mainly include erythropoiesis-stimulating agents (ESAs), iron supplementation, and blood transfusion, but their effects are often poor with several safety concerns. We have used roxadustat to treat anemia in a cancer patient with ESRD and achieved a successful outcome for the first time. CASE SUMMARY: A 64-year-old man was diagnosed with right renal cancer (clear cell renal cell carcinoma). He did not receive surgery or radiotherapy before admission. He was treated with oral soltan (sunitinib malate) on April 18, 2017. During oral chemotherapy, he had numerous complications, including anemia, hypertension, thyroid hypofunction, skin pigment loss, and renal function deterioration. At last, he progressed to ESRD and began hemodialysis treatment. We initially treated the patient with high-dose ESAs, iron supplementation, adequate dialysis, and even blood transfusion, but his anemia did not improve. Roxadustat is a newly developed drug for renal anemia treatment, but not for cancer-related anemia, let alone to treat anemia in cancer patients with ESRD. We prescribed oral roxadustat to the patient. After a period, his hemoglobin gradually increased. He did not have obvious discomfort symptoms, and his tumor did not progress significantly. CONCLUSION: Oral roxadustat could achieve good results in treating anemia in cancer patients with ESRD. |
format | Online Article Text |
id | pubmed-9294907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-92949072022-08-16 Roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: A case report Zhou, Qiao-Qiao Li, Jing Liu, Bin Wang, Chun-Li World J Clin Cases Case Report BACKGROUND: Most cancer patients are accompanied by anemia, which will be more serious when combined with end-stage renal disease (ESRD). At present, cancer-related anemia and renal anemia treatments mainly include erythropoiesis-stimulating agents (ESAs), iron supplementation, and blood transfusion, but their effects are often poor with several safety concerns. We have used roxadustat to treat anemia in a cancer patient with ESRD and achieved a successful outcome for the first time. CASE SUMMARY: A 64-year-old man was diagnosed with right renal cancer (clear cell renal cell carcinoma). He did not receive surgery or radiotherapy before admission. He was treated with oral soltan (sunitinib malate) on April 18, 2017. During oral chemotherapy, he had numerous complications, including anemia, hypertension, thyroid hypofunction, skin pigment loss, and renal function deterioration. At last, he progressed to ESRD and began hemodialysis treatment. We initially treated the patient with high-dose ESAs, iron supplementation, adequate dialysis, and even blood transfusion, but his anemia did not improve. Roxadustat is a newly developed drug for renal anemia treatment, but not for cancer-related anemia, let alone to treat anemia in cancer patients with ESRD. We prescribed oral roxadustat to the patient. After a period, his hemoglobin gradually increased. He did not have obvious discomfort symptoms, and his tumor did not progress significantly. CONCLUSION: Oral roxadustat could achieve good results in treating anemia in cancer patients with ESRD. Baishideng Publishing Group Inc 2022-07-06 2022-07-06 /pmc/articles/PMC9294907/ /pubmed/35979316 http://dx.doi.org/10.12998/wjcc.v10.i19.6587 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Case Report Zhou, Qiao-Qiao Li, Jing Liu, Bin Wang, Chun-Li Roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: A case report |
title | Roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: A case report |
title_full | Roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: A case report |
title_fullStr | Roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: A case report |
title_full_unstemmed | Roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: A case report |
title_short | Roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: A case report |
title_sort | roxadustat for treatment of anemia in a cancer patient with end-stage renal disease: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294907/ https://www.ncbi.nlm.nih.gov/pubmed/35979316 http://dx.doi.org/10.12998/wjcc.v10.i19.6587 |
work_keys_str_mv | AT zhouqiaoqiao roxadustatfortreatmentofanemiainacancerpatientwithendstagerenaldiseaseacasereport AT lijing roxadustatfortreatmentofanemiainacancerpatientwithendstagerenaldiseaseacasereport AT liubin roxadustatfortreatmentofanemiainacancerpatientwithendstagerenaldiseaseacasereport AT wangchunli roxadustatfortreatmentofanemiainacancerpatientwithendstagerenaldiseaseacasereport |